Single agent vinflunine in the salvage treatment of patients with castration-resistant prostate cancer: A phase ii trial of the sarah cannon research consortium

Cancer Investigation

Volumn 28, Issue 3, 2010, Pages 275-279

  Hainsworth, John D ^a,b   Meluch, Anthony A ^b   Lane, Cassie M ^a   Spigel, David R ^a,b   Burris III, Howard A ^a,b   Gandhi, Jitendra G ^c   Crane, Edward J ^d   Stipanov, Michael A ^c   Greco, F Anthony ^b  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b PLLC   (United States)

^c Associates in Oncology and Hematology   (United States)

^d Oncology Hematology Care   (United States)

Author keywords

Castration resistant prostate cancer; Phase II trial; Prostate cancer; Vinflunine

Indexed keywords

DOCETAXEL; VINFLUNINE;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ARTICLE; BLEEDING; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CASTRATION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DEHYDRATION; DRUG FATALITY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; HYPERGLYCEMIA; MALE; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; SALVAGE THERAPY; SURVIVAL RATE; SURVIVAL TIME; SYNCOPE; THROMBOCYTOPENIA; TINNITUS; WEAKNESS;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORCHIECTOMY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SALVAGE THERAPY; VINBLASTINE;

EID: 77149162090     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357900902918460     Document Type: Article

References (13)

1. Petrylak, D.P.; Tangen, C.M.; Hussain, M.N.A. et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004, 351, 1513-1520.
2. Tannock, I.F.; de Wit, R.; Berry, W.R. et al. Docetaxel plus pred-nisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351, 1502-1512.
3. Hill, B.T.; Flebig, H.H.; Waud, W.R. et al. Superior in vivo experimental antitumour activity of vinflunine relative to vinorelbine in a panel of human tumour xenografts. Eur J Cancer 1999, 35, 512-520.
4. Culine, S.; Theodore, C.; DeSantis, M. et al. A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer 2006, 94, 1395-1414.
5. Peacock, N.W.; Spigel, D.R.; Mainwaring, M.G. et al. Preliminary results of a multicenter phase II trial of vinflunine (with trastuzumab in HER2+ patients) as first-line treatment in metastatic breast cancer. J Clin Oncol 2007, 25, 42s (Abstract #1043).
6. Krzakowski, M.; Douillard, J.; Ramlau, R. et al. Phase III study of vinflunine versus docetaxel in patients with advanced non-small cell lung cancer previously treated with a platinum-containing regimen. J Clin Oncol 2007, 25, 387s (Abstract #7511).
7. Bubley, G.C.; Carducci, M.; Dahut, W. et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999, 17, 3461-3467.
8. Therasse, P.; Arbuck, S.G.; Eisenhauer, E.A. et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92, 205-216.
9. Kaplan, E.L.; Meier, P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53, 457-481.
10. Dexeus, F.; Logothetis, C.J.; Samuels, M.L. et al. Continuous infusion of vinblastine for advanced hormone-refractory prostate cancer. Cancer Treat Rep 1985, 69, 885-886.
11. Hudes, G.; Einhorn, L.; Ross, E. et al. Vinblastine versus vinplas-tine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: a Hoosier Oncology Group and Fox Chase Network phase II trial. J Clin Oncol 1999, 17, 3160-3166.
12. Caty, A.; Oudard, S.; Humblet, Y. et al. Phase II study of vinorelbine in patients with hormone refractory prostate cancer. Proc Am Soc Clin Oncol 1997, 16, 311a.
13. Carles, J.; Domenech, M.; Gelabert-Mas, A. et al. Phase II study of estramustine and vinorelbine in hormone-refractory prostate carcinoma patients. Acta Oncologica 1998, 37, 187-191.